Proximal Muscle Weakness – The Clue in the Chair: A Diagnostic Gateway to Endocrine Myopathies

Dr Neeraj Manikath , claude.ai

Abstract

Proximal muscle weakness represents a highly specific clinical finding that, when properly recognized, serves as a diagnostic beacon pointing toward serious underlying endocrine pathology. This review explores the pathophysiology, clinical recognition, and systematic approach to patients presenting with the inability to rise from a chair without arm support—a simple bedside observation that can unlock complex diagnoses including Cushing's syndrome, thyrotoxicosis, and hyperparathyroidism. We provide evidence-based diagnostic algorithms, clinical pearls, and practical management strategies for internists encountering this elegant clinical sign.

Introduction

The ability to stand from a seated position without using one's arms is a seemingly simple motor task that requires coordinated function of the hip flexors, quadriceps, and gluteal muscles—the quintessential proximal muscle groups. When this ability is lost, it creates what neurologists call the "positive chair sign" or "Gowers' sign in adults," a highly specific indicator of proximal myopathy.Studies demonstrate that the inability to rise from a chair without arm support has a positive predictive value exceeding 85% for clinically significant proximal weakness, making it one of the most reliable bedside tests in clinical medicine.

What makes proximal muscle weakness particularly fascinating for the diagnostic internist is its remarkably focused differential diagnosis. Unlike generalized weakness or fatigue—symptoms with vast differential diagnoses—true proximal myopathy with preserved distal strength points to a short list of metabolic and endocrine disorders. This review focuses on the endocrine causes that every internist must recognize: glucocorticoid excess, thyroid dysfunction, and parathyroid disease.

Clinical Pearl #1: Always distinguish true muscle weakness from fatigue, pain, or lack of effort. True myopathy manifests as inability to perform a motor task despite maximum effort, not unwillingness or discomfort.

The Stand-Up Test: Clinical Assessment of Proximal Weakness

The Bedside Examination

The stand-up test, also known as the chair rise test, represents one of the most valuable yet underutilized tools in clinical medicine. The test is performed by asking the patient to rise from a standard-height chair (seat height approximately 45-50 cm) with arms folded across the chest, without pushing off with hands or using momentum from leaning forward excessively.

Technique for the Stand-Up Test:

Position the patient in a firm, armless chair of standard height
Instruct them to fold arms across chest
Ask them to stand without using arms or external support
Observe number of attempts required and use of compensatory strategies
Note any tremor, instability, or alternative muscle recruitment patterns

The chair rise test correlates strongly with objective measurements of quadriceps strength and functional mobility scores, making it both a diagnostic and prognostic tool.

Grading Proximal Muscle Weakness

The Medical Research Council (MRC) grading system provides standardized assessment:

Grade 5: Normal power
Grade 4: Active movement against gravity and resistance
Grade 3: Active movement against gravity only
Grade 2: Active movement with gravity eliminated
Grade 1: Flicker of contraction
Grade 0: No contraction

For endocrine myopathies, patients typically present with grade 3-4 weakness, distinguishing them from severe neurogenic causes where grade 0-2 weakness is more common.

Additional Examination Findings

Complement the stand-up test with:

Squat test: Ability to squat and rise (more sensitive for mild weakness)
Stair climbing: Observe difficulty ascending stairs
Arm elevation: Test shoulder abduction and flexion (deltoids, supraspinatus)
Neck flexion: Hip flexors and neck flexors are often affected together
Gait observation: Waddling gait suggests pelvic girdle weakness

Oyster #1: A patient who can rise from a chair but cannot climb stairs likely has an orthopedic rather than myopathic cause. True proximal myopathy affects both equally.

Cushing's Syndrome Myopathy: When Cortisol Cannibalizes Muscle

Pathophysiology

Glucocorticoid-induced myopathy represents one of the most common causes of proximal muscle weakness in hospitalized patients. Excess cortisol induces profound catabolic effects on skeletal muscle through multiple mechanisms including decreased protein synthesis, increased protein degradation via the ubiquitin-proteasome pathway, and mitochondrial dysfunction.

The biochemical cascade involves:

Activation of atrogin-1 and MuRF-1 (muscle-specific E3 ubiquitin ligases)
Decreased insulin-like growth factor 1 (IGF-1) signaling
Impaired glucose utilization by muscle cells
Increased myostatin expression
Type 2 (fast-twitch) fiber atrophy predominantly

Hack #1: Steroid myopathy preferentially affects type 2b fibers—the largest, strongest muscle fibers responsible for explosive power. This explains why patients lose the ability to perform power tasks (standing, climbing) before losing endurance.

Clinical Presentation

Patients with Cushing's syndrome develop insidious onset of proximal weakness over months to years. The classic cushingoid habitus provides diagnostic clues:

Central obesity with limb muscle wasting ("lemon on sticks" appearance)
Moon facies and dorsocervical fat pad ("buffalo hump")
Purple striae (>1 cm wide, on abdomen)
Easy bruising and thin skin
Proximal muscle atrophy visible on inspection

Myopathy occurs in 40-70% of patients with endogenous Cushing's syndrome and is often the presenting complaint. Importantly, iatrogenic Cushing's from chronic steroid therapy produces identical myopathy.

Diagnostic Approach

Screening Tests:

24-hour urinary free cortisol (elevated >3-4 times upper limit of normal is diagnostic)
Late-night salivary cortisol (loss of normal diurnal variation)
1 mg overnight dexamethasone suppression test (failure to suppress morning cortisol <1.8 μg/dL)

Distinguishing Features: In Cushing's myopathy, serum creatine kinase (CK) is characteristically normal or only mildly elevated, distinguishing it from inflammatory myopathies where CK elevation is prominent. This paradoxical finding reflects the catabolic nature of the process—muscle protein is degraded, but inflammation is absent.

Pearl #2: In a patient on chronic prednisone who develops proximal weakness, suspect steroid myopathy first. The fluorinated steroids (dexamethasone, triamcinolone) cause more severe myopathy than non-fluorinated ones (prednisone, hydrocortisone).

Dose-Response Relationship

Steroid myopathy typically develops with prolonged use of prednisone >10 mg daily or equivalent, though individual susceptibility varies. Higher doses and longer duration increase severity. The myopathy develops gradually—usually over weeks to months of exposure.

Management Pearls

Reversibility: Muscle strength improves within 3-4 weeks of reducing glucocorticoid dose, with full recovery possible over 3-6 months
Exercise paradox: While resistance training helps, patients often cannot perform adequate exercise due to weakness—a vicious cycle
Nutritional support: High protein intake (1.2-1.5 g/kg/day) may attenuate muscle loss
Vitamin D: Correct deficiency, as it compounds glucocorticoid-induced myopathy

Thyrotoxic Myopathy: The Hypercatabolic State

Pathophysiology

Thyroid hormone excess creates a hypermetabolic state affecting skeletal muscle through multiple mechanisms. Excess T3 accelerates protein turnover with degradation exceeding synthesis, increases oxidative stress, and enhances calcium-dependent proteolysis.

The thyroid hormone effects include:

Increased basal metabolic rate and protein catabolism
Enhanced Na-K-ATPase activity (energy depletion)
Mitochondrial uncoupling (inefficient ATP production)
Altered calcium homeostasis in sarcoplasmic reticulum
Fast-to-slow fiber type transformation

Clinical Recognition

Thyrotoxic myopathy occurs in 50-70% of hyperthyroid patients, though clinically significant weakness develops in only 10-20%. The myopathy often goes unrecognized because the dramatic systemic manifestations of thyrotoxicosis overshadow the muscle weakness.

Classic Presentation:

Insidious proximal weakness over weeks to months
Weight loss despite increased appetite
Heat intolerance and excessive sweating
Tremor, anxiety, palpitations
Frequent bowel movements
Lid lag, stare, possible ophthalmopathy (Graves' disease)

Oyster #2: A young patient (age <40) presenting with new-onset atrial fibrillation and proximal weakness should trigger immediate thyroid function testing. This combination is pathognomonic for thyrotoxicosis until proven otherwise.

Special Variants

Thyrotoxic Periodic Paralysis (TPP): A dramatic variant occurring predominantly in Asian males, characterized by sudden episodes of severe weakness associated with hypokalemia. TPP results from excessive Na-K-ATPase activity driving potassium intracellularly, causing sudden profound hypokalemia and paralysis. Episodes are often triggered by high-carbohydrate meals or strenuous exercise.

Hack #2: In TPP, potassium supplementation must be cautious and monitored. As thyrotoxicosis is treated and cellular potassium shifts back out, rebound hyperkalemia can occur within 24-48 hours.

Diagnostic Triad Findings

TSH: Suppressed (<0.01 mIU/L in overt hyperthyroidism)
Free T4 and T3: Elevated
CK: Normal to mildly elevated (typically <2x ULN)

Pearl #3: In suspected hyperthyroidism, always check both free T4 and T3. T3 toxicosis (isolated T3 elevation) accounts for 5-10% of cases and will be missed if only TSH and T4 are checked.

Differential Diagnostic Challenge

Thyrotoxic myopathy must be distinguished from:

Graves' ophthalmopathy with extraocular myopathy: Eye muscle weakness, not proximal limb weakness
Hypokalemic periodic paralysis: Episodic, not chronic weakness
Concurrent autoimmune myasthenia gravis: Occurs in 1% of Graves' patients—look for diplopia, ptosis, fatigability

Management Approach

Acute treatment: Beta-blockers (propranolol 20-40 mg TID) provide rapid symptomatic relief
Definitive treatment: Antithyroid drugs (methimazole, propylthiouracil) or radioactive iodine
Recovery timeline: Muscle strength begins improving within 4-6 weeks of achieving euthyroidism; complete recovery may take 3-6 months
Potassium in TPP: Correct hypokalemia cautiously (40-90 mEq over 24 hours) with cardiac monitoring

The Hyperparathyroidism Connection: Bones, Stones, Groans, and Moans

Pathophysiology

Primary hyperparathyroidism causes proximal myopathy through calcium-mediated mechanisms and direct parathyroid hormone (PTH) effects on muscle. Chronic hypercalcemia impairs muscle cell membrane excitability, calcium deposits in muscle tissue cause inflammation, and PTH directly affects muscle metabolism.

The mechanisms involve:

Calcium deposition in muscle fibers (calcinosis)
Impaired excitation-contraction coupling
Mitochondrial calcium overload
Phosphate depletion in severe cases
Vitamin D deficiency (paradoxically common despite hypercalcemia)

Clinical Presentation

The classic mnemonic "bones, stones, groans, and moans" captures the protean manifestations:

Bones: Osteoporosis, bone pain, osteitis fibrosa cystica
Stones: Nephrolithiasis (20% of patients)
Groans: Abdominal pain, constipation, peptic ulcers
Moans: Depression, cognitive dysfunction, proximal myopathy

Neuromuscular symptoms occur in 40-70% of patients with primary hyperparathyroidism, with proximal muscle weakness being reported by 30-40%.

Pearl #4: The severity of hypercalcemia correlates poorly with myopathy severity. Patients with chronic mild hypercalcemia (10.5-11.5 mg/dL) can have significant weakness, while acute severe hypercalcemia may present with altered mental status before myopathy develops.

Diagnostic Features

Laboratory Findings:

Calcium: Elevated (corrected for albumin: add 0.8 mg/dL for every 1 g/dL albumin below 4.0)
PTH: Elevated or inappropriately normal (should be suppressed if hypercalcemia were physiologic)
Phosphate: Low-normal to low
25-OH Vitamin D: Often deficient
CK: Normal

Imaging:

Neck ultrasound or sestamibi scan to localize parathyroid adenoma
Bone density scan (DEXA) showing osteoporosis, particularly at distal radius
Renal imaging if stones suspected

Hack #3: The "calcium-phosphate flip" is diagnostic—when you see high calcium with low-normal or low phosphate, think hyperparathyroidism. Almost no other condition causes this pattern.

The Diagnostic Challenge

Many patients with hyperparathyroidism are asymptomatic or have vague symptoms, and the diagnosis is often made incidentally on routine chemistry panels. The insidious nature of symptoms means patients and even physicians may attribute weakness to aging or deconditioning.

Oyster #3: A postmenopausal woman with osteoporosis, kidney stones, and depression attributed to "menopause" or "aging" deserves calcium and PTH measurement. This classic presentation is often missed for years.

Management Principles

Indications for Parathyroidectomy:

Symptomatic disease (including myopathy)
Calcium >1 mg/dL above upper limit of normal
Age <50 years
Osteoporosis (T-score <-2.5)
Reduced creatinine clearance (<60 mL/min)
Nephrolithiasis or nephrocalcinosis

Post-Surgical Recovery:

Muscle strength improves within 6-12 weeks
Bone density improves over 1-2 years
Hungry bone syndrome risk (severe hypocalcemia post-op) requires monitoring

The Diagnostic Triad: CK, TSH, and Cortisol

When confronted with proximal muscle weakness, a focused laboratory approach prevents diagnostic delay and unnecessary testing. The "endocrine myopathy triad" provides a rational first-line strategy:

Creatine Kinase (CK)

Interpretation:

Normal CK (typically <200 U/L): Favors endocrine myopathy over inflammatory or muscular dystrophy
Mild elevation (2-10x ULN): Can occur in thyrotoxicosis, hypothyroidism, or early dermatomyositis
Marked elevation (>10x ULN): Suggests inflammatory myopathy, rhabdomyolysis, or muscular dystrophy

The sensitivity of CK for detecting endocrine myopathies is only 40-50%, meaning normal CK does not exclude the diagnosis. This is a critical point often missed—endocrine myopathies are "non-inflammatory" and don't release significant CK.

Pearl #5: Hypothyroid myopathy (not discussed extensively here, but important) can elevate CK markedly (up to 20x normal), mimicking inflammatory myopathy. Always check TSH in patients with elevated CK and weakness.

Thyroid Stimulating Hormone (TSH)

Interpretation:

Suppressed TSH (<0.01 mIU/L): Hyperthyroidism—check free T4 and T3
Elevated TSH (>10 mIU/L): Hypothyroidism—check free T4
Normal TSH: Excludes primary thyroid disease (though central hypothyroidism remains possible in pituitary disease)

The TSH is the single best screening test for thyroid dysfunction, with sensitivity and specificity both exceeding 95%.

Cortisol Assessment

Screening Strategy:

24-hour urinary free cortisol: Most sensitive for endogenous Cushing's
Late-night salivary cortisol: Excellent for detecting loss of diurnal rhythm
1 mg overnight dexamethasone suppression test: Convenient outpatient screening

No single test is perfect—using two complementary tests increases diagnostic sensitivity to >95%.

Hack #4: If the patient is on chronic steroids, you don't need sophisticated testing—the diagnosis is iatrogenic Cushing's syndrome. Focus on reduction strategies rather than diagnostic confirmation.

Expanded Panel

After the initial triad, consider:

Calcium and PTH: Screen for hyperparathyroidism
Vitamin D (25-OH): Deficiency causes myalgias and contributes to weakness
Electrolytes: Hypokalemia (thyrotoxic periodic paralysis, diuretics) or hypophosphatemia
Aldolase: More specific for inflammatory myopathy than CK
ESR/CRP: Elevated in inflammatory but not endocrine myopathies
EMG/NCS: Reserve for cases where diagnosis remains unclear

Pearl #6: Resist the urge to order an expensive antibody panel (anti-Jo-1, anti-Mi-2, etc.) before completing the basic endocrine workup. Endocrine causes are far more common and easily treated.

Practical Diagnostic Algorithm

Step 1: Confirm True Proximal Weakness

Perform chair rise test
Assess specific muscle groups (hip flexors, quadriceps, shoulder abductors)
Distinguish from pain, fatigue, joint disease

Step 2: Initial Laboratory Workup

Complete blood count, comprehensive metabolic panel
CK, TSH, calcium
Consider 24-hour urine cortisol or dexamethasone suppression test

Step 3: Pattern Recognition

Normal CK + abnormal TSH = Thyroid myopathy
Normal CK + hypercalcemia = Hyperparathyroidism
Normal CK + cushingoid features = Cushing's syndrome
Normal CK + all tests normal = Consider inflammatory myopathy, EMG/biopsy

Step 4: Confirmatory Testing

Thyroid: Free T4, T3, thyroid antibodies, imaging
Cushing's: Second screening test, then localization (pituitary MRI, adrenal CT)
Hyperparathyroidism: PTH, vitamin D, sestamibi scan

Step 5: Treatment and Reassessment

Initiate specific therapy
Monitor strength recovery (typically 6-12 weeks)
If no improvement, reconsider diagnosis

Clinical Pearls and Oysters: Summary

Pearls:

True muscle weakness means inability to perform a task, not unwillingness or pain
Steroid myopathy: fluorinated steroids are worse offenders
Always check T3 in suspected hyperthyroidism
Hypercalcemia severity doesn't predict myopathy severity
Normal CK does not exclude endocrine myopathy
Complete basic endocrine workup before expensive antibody testing

Oysters:

Chair rise difficulty with normal stair climbing suggests orthopedic, not myopathic cause
New atrial fibrillation + proximal weakness in young patient = thyrotoxicosis
Postmenopausal woman with osteoporosis, stones, depression = check calcium and PTH

Hacks:

Type 2b fiber preferential atrophy explains loss of power before endurance
Thyrotoxic periodic paralysis: cautious K+ replacement to avoid rebound hyperkalemia
Calcium-phosphate flip (high Ca, low PO4) = hyperparathyroidism
Patient on chronic steroids with weakness = iatrogenic Cushing's (don't over-test)

Conclusion

Proximal muscle weakness, elegantly revealed by the simple chair rise test, represents one of internal medicine's most focused diagnostic signs. When a patient cannot stand from a chair without using their arms, the astute clinician recognizes a limited differential diagnosis weighted heavily toward endocrine pathology. The systematic application of the diagnostic triad—CK, TSH, and cortisol assessment—supplemented by calcium measurement, identifies the vast majority of cases.

The beauty of recognizing endocrine myopathies lies in their reversibility. Unlike genetic muscular dystrophies or chronic neurogenic disorders, these conditions respond dramatically to specific treatment. Weakness that has developed over months resolves over weeks to months once the underlying hormonal derangement is corrected, returning patients to full function.

For the internist, mastering the recognition and workup of proximal muscle weakness provides diagnostic elegance, therapeutic satisfaction, and the pleasure of solving one of medicine's classic clinical puzzles—all from the simple observation of how a patient rises from a chair.

References

Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve. 2004;29(4):484-505.
Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;373(4):393-394.
Kendall FP, McCreary EK, Provance PG. Muscles: Testing and Function. 5th ed. Baltimore: Williams & Wilkins; 2005.
Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. Res Q Exerc Sport. 1999;70(2):113-119.
McCarthy EK, Horvat MA, Holtsberg PA, Wisenbaker JM. Repeated chair stands as a measure of lower limb strength in sexagenarian women. J Gerontol A Biol Sci Med Sci. 2004;59(11):1207-1212.
Bohannon RW. Measurement of sit-to-stand among older adults. Top Geriatr Rehabil. 2012;28(1):11-16.
Millor N, Lecumberri P, Gómez M, et al. An evaluation of the 30-s chair stand test in older adults. Gerontology. 2013;59(5):440-446.
Medical Research Council. Aids to the Examination of the Peripheral Nervous System. London: Her Majesty's Stationery Office; 1976.
Compston A. Aids to the investigation of peripheral nerve injuries. Brain. 2010;133(Pt 10):2838-2844.
Vanhoutte EK, Faber CG, van Nes SI, et al. Modifying the Medical Research Council grading system. Brain. 2012;135(Pt 5):1639-1649.
Schakman O, Kalista S, Barbé C, Loumaye A, Thissen JP. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol. 2013;45(10):2163-2172.
Pereira RM, Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine. 2011;78(1):41-44.
Bowyer SL, LaMothe MP, Hollister JR. Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol. 1985;76(2 Pt 1):234-242.
Dekhuijzen PN, Gayan-Ramirez G, Bisschop A, De Bock V, Dom R, Decramer M. Corticosteroid treatment and nutritional deprivation cause a different pattern of atrophy in rat diaphragm. J Appl Physiol. 1995;78(2):629-637.
Plotz CM, Knowlton AI, Ragan C. The natural history of Cushing's syndrome. Am J Med. 1952;13(5):597-614.
Müssig K, Künle A, Säuberlich AL, et al. Thyroid peroxidase antibody positivity is associated with symptomatic distress in patients with Hashimoto's thyroiditis. Brain Behav Immun. 2012;26(4):559-563.
Minetto MA, Lanfranco F, Motta G, Allasia S, Arvat E, D'Antona G. Steroid myopathy: some unresolved issues. J Endocrinol Invest. 2011;34(5):370-375.
Khaleeli AA, Edwards RH, Gohil K, et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol (Oxf). 1983;18(2):155-166.
Desmet KD, Paz DA, Corry JJ, et al. Clinical and experimental applications of NIR-LED photobiomodulation. Photomed Laser Surg. 2006;24(2):121-128.
Braun C, Hanisch F, Müller M, et al. Serum creatine kinase and lactate dehydrogenase for diagnosis of muscle disease. JAMA Neurol. 2017;74(2):231-232.
Schakman O, Gilson H, Kalista S, Thissen JP. Mechanisms of muscle atrophy induced by glucocorticoids. Horm Res. 2009;72 Suppl 1:36-41.
Savulescu D, Skovseth D, Hullstein I, et al. Glucocorticoid-induced muscle atrophy. Acta Physiol (Oxf). 2013;207(1):22-32.
van Balkom RH, van der Velden JL, Schols AM, et al. Low dose methylprednisolone reduces the severity of glucocorticoid-induced myopathy. Acta Physiol (Oxf). 2013;208(4):315-321.
Ramsay ID. Thyrotoxic muscle disease. Postgrad Med J. 1966;42(492):572-577.
Khaleeli AA, Griffith DG, Edwards RH. The clinical presentation of hypothyroid myopathy and its relationship to abnormalities in structure and function of skeletal muscle. Clin Endocrinol (Oxf). 1983;19(3):365-376.
Visser WE, Friesema EC, Visser TJ. Minireview: thyroid hormone transporters. Endocrinology. 2011;152(9):2666-2673.
Brennan MD, Coenen-Schimke JM, Bigelow ML, Nair KS. Changes in skeletal muscle protein metabolism and myosin heavy chain isoform messenger ribonucleic acid abundance after treatment of hyperthyroidism. J Clin Endocrinol Metab. 2006;91(11):4650-4656.
Duyff RF, Van den Bosch J, Laman DM, van Loon BJ, Linssen WH. Neuromuscular findings in thyroid dysfunction. J Neurol Neurosurg Psychiatry. 2000;68(6):750-755.
Ramsay I. Electromyography in thyrotoxicosis. Q J Med. 1965;34(134):255-267.
Ober KP. Thyrotoxic periodic paralysis in the United States. Medicine (Baltimore). 1992;71(3):109-120.
Kung AW. Clinical review: thyrotoxic periodic paralysis. J Clin Endocrinol Metab. 2006;91(7):2490-2495.
Lin SH, Lin YF. Propranolol rapidly reverses paralysis, hypokalemia, and hypophosphatemia in thyrotoxic periodic paralysis. Am J Kidney Dis. 2001;37(3):620-623.
Ahlawat SK, Sachdev A. Hypokalaemic paralysis. Postgrad Med J. 1999;75(882):193-197.
Patten BM, Bilezikian JP, Mallette LE, Prince A, Engel WK, Aurbach GD. Neuromuscular disease in primary hyperparathyroidism. Ann Intern Med. 1974;80(2):182-193.
Turken SA, Cafferty M, Silverberg SJ, et al. Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. Am J Med. 1989;87(5):553-557.
Abbasi B, Sharif N, DiCristofano J, et al. Proximal myopathy revealing primary hyperparathyroidism. Clin Cases Miner Bone Metab. 2014;11(3):233-236.
Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab. 2007;92(8):3001-3005.
Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nat Rev Endocrinol. 2018;14(2):115-125.
Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. Lancet. 2018;391(10116):168-178.
Marcocci C, Cetani F. Clinical practice. Primary hyperparathyroidism. N Engl J Med. 2011;365(25):2389-2397.
Bandeira F, Griz L, Chaves N, Carvalho NC, Borges LM, Lazaretti-Castro M, et al. Diagnosis and management of primary hyperparathyroidism. Arq Bras Endocrinol Metabol. 2014;58(5):587-595.
Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab. 2014;99(10):3561-3569.
Gallagher EJ, LeRoith D. Obesity and diabetes: the increased risk of cancer and cancer-related mortality. Physiol Rev. 2015;95(3):727-748.
Kyriakides T, Angelini C, Schaefer J, et al. EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia. Eur J Neurol. 2010;17(6):767-773.
Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000;342(17):1266-1271.
Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93(5):1526-1540.
Raff H, Findling JW. A physiologic approach to diagnosis of the Cushing syndrome. Ann Intern Med. 2003;138(12):980-991.
Carroll T, Raff H, Findling JW.

: A Diagnostic Gateway to Endocrine Myopathies

Abstract

Introduction

The Stand-Up Test: Clinical Assessment of Proximal Weakness

The Bedside Examination

Technique for the Stand-Up Test:

Position the patient in a firm, armless chair of standard height
Instruct them to fold arms across chest
Ask them to stand without using arms or external support
Observe number of attempts required and use of compensatory strategies
Note any tremor, instability, or alternative muscle recruitment patterns

The chair rise test correlates strongly with objective measurements of quadriceps strength and functional mobility scores, making it both a diagnostic and prognostic tool.

Grading Proximal Muscle Weakness

The Medical Research Council (MRC) grading system provides standardized assessment:

Grade 5: Normal power
Grade 4: Active movement against gravity and resistance
Grade 3: Active movement against gravity only
Grade 2: Active movement with gravity eliminated
Grade 1: Flicker of contraction
Grade 0: No contraction

For endocrine myopathies, patients typically present with grade 3-4 weakness, distinguishing them from severe neurogenic causes where grade 0-2 weakness is more common.

Additional Examination Findings

Complement the stand-up test with:

Squat test: Ability to squat and rise (more sensitive for mild weakness)
Stair climbing: Observe difficulty ascending stairs
Arm elevation: Test shoulder abduction and flexion (deltoids, supraspinatus)
Neck flexion: Hip flexors and neck flexors are often affected together
Gait observation: Waddling gait suggests pelvic girdle weakness

Oyster #1: A patient who can rise from a chair but cannot climb stairs likely has an orthopedic rather than myopathic cause. True proximal myopathy affects both equally.

Cushing's Syndrome Myopathy: When Cortisol Cannibalizes Muscle

Pathophysiology

The biochemical cascade involves:

Activation of atrogin-1 and MuRF-1 (muscle-specific E3 ubiquitin ligases)
Decreased insulin-like growth factor 1 (IGF-1) signaling
Impaired glucose utilization by muscle cells
Increased myostatin expression
Type 2 (fast-twitch) fiber atrophy predominantly

Clinical Presentation

Patients with Cushing's syndrome develop insidious onset of proximal weakness over months to years. The classic cushingoid habitus provides diagnostic clues:

Central obesity with limb muscle wasting ("lemon on sticks" appearance)
Moon facies and dorsocervical fat pad ("buffalo hump")
Purple striae (>1 cm wide, on abdomen)
Easy bruising and thin skin
Proximal muscle atrophy visible on inspection

Diagnostic Approach

Screening Tests:

24-hour urinary free cortisol (elevated >3-4 times upper limit of normal is diagnostic)
Late-night salivary cortisol (loss of normal diurnal variation)
1 mg overnight dexamethasone suppression test (failure to suppress morning cortisol <1.8 μg/dL)

Dose-Response Relationship

Management Pearls

Reversibility: Muscle strength improves within 3-4 weeks of reducing glucocorticoid dose, with full recovery possible over 3-6 months
Exercise paradox: While resistance training helps, patients often cannot perform adequate exercise due to weakness—a vicious cycle
Nutritional support: High protein intake (1.2-1.5 g/kg/day) may attenuate muscle loss
Vitamin D: Correct deficiency, as it compounds glucocorticoid-induced myopathy

Thyrotoxic Myopathy: The Hypercatabolic State

Pathophysiology

The thyroid hormone effects include:

Increased basal metabolic rate and protein catabolism
Enhanced Na-K-ATPase activity (energy depletion)
Mitochondrial uncoupling (inefficient ATP production)
Altered calcium homeostasis in sarcoplasmic reticulum
Fast-to-slow fiber type transformation

Clinical Recognition

Classic Presentation:

Insidious proximal weakness over weeks to months
Weight loss despite increased appetite
Heat intolerance and excessive sweating
Tremor, anxiety, palpitations
Frequent bowel movements
Lid lag, stare, possible ophthalmopathy (Graves' disease)

Special Variants

Hack #2: In TPP, potassium supplementation must be cautious and monitored. As thyrotoxicosis is treated and cellular potassium shifts back out, rebound hyperkalemia can occur within 24-48 hours.

Diagnostic Triad Findings

TSH: Suppressed (<0.01 mIU/L in overt hyperthyroidism)
Free T4 and T3: Elevated
CK: Normal to mildly elevated (typically <2x ULN)

Pearl #3: In suspected hyperthyroidism, always check both free T4 and T3. T3 toxicosis (isolated T3 elevation) accounts for 5-10% of cases and will be missed if only TSH and T4 are checked.

Differential Diagnostic Challenge

Thyrotoxic myopathy must be distinguished from:

Graves' ophthalmopathy with extraocular myopathy: Eye muscle weakness, not proximal limb weakness
Hypokalemic periodic paralysis: Episodic, not chronic weakness
Concurrent autoimmune myasthenia gravis: Occurs in 1% of Graves' patients—look for diplopia, ptosis, fatigability

Management Approach

Acute treatment: Beta-blockers (propranolol 20-40 mg TID) provide rapid symptomatic relief
Definitive treatment: Antithyroid drugs (methimazole, propylthiouracil) or radioactive iodine
Recovery timeline: Muscle strength begins improving within 4-6 weeks of achieving euthyroidism; complete recovery may take 3-6 months
Potassium in TPP: Correct hypokalemia cautiously (40-90 mEq over 24 hours) with cardiac monitoring

The Hyperparathyroidism Connection: Bones, Stones, Groans, and Moans

Pathophysiology

The mechanisms involve:

Calcium deposition in muscle fibers (calcinosis)
Impaired excitation-contraction coupling
Mitochondrial calcium overload
Phosphate depletion in severe cases
Vitamin D deficiency (paradoxically common despite hypercalcemia)

Clinical Presentation

The classic mnemonic "bones, stones, groans, and moans" captures the protean manifestations:

Bones: Osteoporosis, bone pain, osteitis fibrosa cystica
Stones: Nephrolithiasis (20% of patients)
Groans: Abdominal pain, constipation, peptic ulcers
Moans: Depression, cognitive dysfunction, proximal myopathy

Neuromuscular symptoms occur in 40-70% of patients with primary hyperparathyroidism, with proximal muscle weakness being reported by 30-40%.

Diagnostic Features

Laboratory Findings:

Calcium: Elevated (corrected for albumin: add 0.8 mg/dL for every 1 g/dL albumin below 4.0)
PTH: Elevated or inappropriately normal (should be suppressed if hypercalcemia were physiologic)
Phosphate: Low-normal to low
25-OH Vitamin D: Often deficient
CK: Normal

Imaging:

Neck ultrasound or sestamibi scan to localize parathyroid adenoma
Bone density scan (DEXA) showing osteoporosis, particularly at distal radius
Renal imaging if stones suspected

Hack #3: The "calcium-phosphate flip" is diagnostic—when you see high calcium with low-normal or low phosphate, think hyperparathyroidism. Almost no other condition causes this pattern.

The Diagnostic Challenge

Management Principles

Indications for Parathyroidectomy:

Symptomatic disease (including myopathy)
Calcium >1 mg/dL above upper limit of normal
Age <50 years
Osteoporosis (T-score <-2.5)
Reduced creatinine clearance (<60 mL/min)
Nephrolithiasis or nephrocalcinosis

Post-Surgical Recovery:

Muscle strength improves within 6-12 weeks
Bone density improves over 1-2 years
Hungry bone syndrome risk (severe hypocalcemia post-op) requires monitoring

The Diagnostic Triad: CK, TSH, and Cortisol

When confronted with proximal muscle weakness, a focused laboratory approach prevents diagnostic delay and unnecessary testing. The "endocrine myopathy triad" provides a rational first-line strategy:

Creatine Kinase (CK)

Interpretation:

Normal CK (typically <200 U/L): Favors endocrine myopathy over inflammatory or muscular dystrophy
Mild elevation (2-10x ULN): Can occur in thyrotoxicosis, hypothyroidism, or early dermatomyositis
Marked elevation (>10x ULN): Suggests inflammatory myopathy, rhabdomyolysis, or muscular dystrophy

Thyroid Stimulating Hormone (TSH)

Interpretation:

Suppressed TSH (<0.01 mIU/L): Hyperthyroidism—check free T4 and T3
Elevated TSH (>10 mIU/L): Hypothyroidism—check free T4
Normal TSH: Excludes primary thyroid disease (though central hypothyroidism remains possible in pituitary disease)

The TSH is the single best screening test for thyroid dysfunction, with sensitivity and specificity both exceeding 95%.

Cortisol Assessment

Screening Strategy:

24-hour urinary free cortisol: Most sensitive for endogenous Cushing's
Late-night salivary cortisol: Excellent for detecting loss of diurnal rhythm
1 mg overnight dexamethasone suppression test: Convenient outpatient screening

No single test is perfect—using two complementary tests increases diagnostic sensitivity to >95%.

Expanded Panel

After the initial triad, consider:

Calcium and PTH: Screen for hyperparathyroidism
Vitamin D (25-OH): Deficiency causes myalgias and contributes to weakness
Electrolytes: Hypokalemia (thyrotoxic periodic paralysis, diuretics) or hypophosphatemia
Aldolase: More specific for inflammatory myopathy than CK
ESR/CRP: Elevated in inflammatory but not endocrine myopathies
EMG/NCS: Reserve for cases where diagnosis remains unclear

Pearl #6: Resist the urge to order an expensive antibody panel (anti-Jo-1, anti-Mi-2, etc.) before completing the basic endocrine workup. Endocrine causes are far more common and easily treated.

Practical Diagnostic Algorithm

Step 1: Confirm True Proximal Weakness

Perform chair rise test
Assess specific muscle groups (hip flexors, quadriceps, shoulder abductors)
Distinguish from pain, fatigue, joint disease

Step 2: Initial Laboratory Workup

Complete blood count, comprehensive metabolic panel
CK, TSH, calcium
Consider 24-hour urine cortisol or dexamethasone suppression test

Step 3: Pattern Recognition

Normal CK + abnormal TSH = Thyroid myopathy
Normal CK + hypercalcemia = Hyperparathyroidism
Normal CK + cushingoid features = Cushing's syndrome
Normal CK + all tests normal = Consider inflammatory myopathy, EMG/biopsy

Step 4: Confirmatory Testing

Thyroid: Free T4, T3, thyroid antibodies, imaging
Cushing's: Second screening test, then localization (pituitary MRI, adrenal CT)
Hyperparathyroidism: PTH, vitamin D, sestamibi scan

Step 5: Treatment and Reassessment

Initiate specific therapy
Monitor strength recovery (typically 6-12 weeks)
If no improvement, reconsider diagnosis

Clinical Pearls and Oysters: Summary

Pearls:

True muscle weakness means inability to perform a task, not unwillingness or pain
Steroid myopathy: fluorinated steroids are worse offenders
Always check T3 in suspected hyperthyroidism
Hypercalcemia severity doesn't predict myopathy severity
Normal CK does not exclude endocrine myopathy
Complete basic endocrine workup before expensive antibody testing

Oysters:

Chair rise difficulty with normal stair climbing suggests orthopedic, not myopathic cause
New atrial fibrillation + proximal weakness in young patient = thyrotoxicosis
Postmenopausal woman with osteoporosis, stones, depression = check calcium and PTH

Hacks:

Type 2b fiber preferential atrophy explains loss of power before endurance
Thyrotoxic periodic paralysis: cautious K+ replacement to avoid rebound hyperkalemia
Calcium-phosphate flip (high Ca, low PO4) = hyperparathyroidism
Patient on chronic steroids with weakness = iatrogenic Cushing's (don't over-test)

Conclusion

References

Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve. 2004;29(4):484-505.
Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;373(4):393-394.
Kendall FP, McCreary EK, Provance PG. Muscles: Testing and Function. 5th ed. Baltimore: Williams & Wilkins; 2005.
Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. Res Q Exerc Sport. 1999;70(2):113-119.
McCarthy EK, Horvat MA, Holtsberg PA, Wisenbaker JM. Repeated chair stands as a measure of lower limb strength in sexagenarian women. J Gerontol A Biol Sci Med Sci. 2004;59(11):1207-1212.
Bohannon RW. Measurement of sit-to-stand among older adults. Top Geriatr Rehabil. 2012;28(1):11-16.
Millor N, Lecumberri P, Gómez M, et al. An evaluation of the 30-s chair stand test in older adults. Gerontology. 2013;59(5):440-446.
Medical Research Council. Aids to the Examination of the Peripheral Nervous System. London: Her Majesty's Stationery Office; 1976.
Compston A. Aids to the investigation of peripheral nerve injuries. Brain. 2010;133(Pt 10):2838-2844.
Vanhoutte EK, Faber CG, van Nes SI, et al. Modifying the Medical Research Council grading system. Brain. 2012;135(Pt 5):1639-1649.
Schakman O, Kalista S, Barbé C, Loumaye A, Thissen JP. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol. 2013;45(10):2163-2172.
Pereira RM, Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine. 2011;78(1):41-44.
Bowyer SL, LaMothe MP, Hollister JR. Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol. 1985;76(2 Pt 1):234-242.
Dekhuijzen PN, Gayan-Ramirez G, Bisschop A, De Bock V, Dom R, Decramer M. Corticosteroid treatment and nutritional deprivation cause a different pattern of atrophy in rat diaphragm. J Appl Physiol. 1995;78(2):629-637.
Plotz CM, Knowlton AI, Ragan C. The natural history of Cushing's syndrome. Am J Med. 1952;13(5):597-614.
Müssig K, Künle A, Säuberlich AL, et al. Thyroid peroxidase antibody positivity is associated with symptomatic distress in patients with Hashimoto's thyroiditis. Brain Behav Immun. 2012;26(4):559-563.
Minetto MA, Lanfranco F, Motta G, Allasia S, Arvat E, D'Antona G. Steroid myopathy: some unresolved issues. J Endocrinol Invest. 2011;34(5):370-375.
Khaleeli AA, Edwards RH, Gohil K, et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol (Oxf). 1983;18(2):155-166.
Desmet KD, Paz DA, Corry JJ, et al. Clinical and experimental applications of NIR-LED photobiomodulation. Photomed Laser Surg. 2006;24(2):121-128.
Braun C, Hanisch F, Müller M, et al. Serum creatine kinase and lactate dehydrogenase for diagnosis of muscle disease. JAMA Neurol. 2017;74(2):231-232.
Schakman O, Gilson H, Kalista S, Thissen JP. Mechanisms of muscle atrophy induced by glucocorticoids. Horm Res. 2009;72 Suppl 1:36-41.
Savulescu D, Skovseth D, Hullstein I, et al. Glucocorticoid-induced muscle atrophy. Acta Physiol (Oxf). 2013;207(1):22-32.
van Balkom RH, van der Velden JL, Schols AM, et al. Low dose methylprednisolone reduces the severity of glucocorticoid-induced myopathy. Acta Physiol (Oxf). 2013;208(4):315-321.
Ramsay ID. Thyrotoxic muscle disease. Postgrad Med J. 1966;42(492):572-577.
Khaleeli AA, Griffith DG, Edwards RH. The clinical presentation of hypothyroid myopathy and its relationship to abnormalities in structure and function of skeletal muscle. Clin Endocrinol (Oxf). 1983;19(3):365-376.
Visser WE, Friesema EC, Visser TJ. Minireview: thyroid hormone transporters. Endocrinology. 2011;152(9):2666-2673.
Brennan MD, Coenen-Schimke JM, Bigelow ML, Nair KS. Changes in skeletal muscle protein metabolism and myosin heavy chain isoform messenger ribonucleic acid abundance after treatment of hyperthyroidism. J Clin Endocrinol Metab. 2006;91(11):4650-4656.
Duyff RF, Van den Bosch J, Laman DM, van Loon BJ, Linssen WH. Neuromuscular findings in thyroid dysfunction. J Neurol Neurosurg Psychiatry. 2000;68(6):750-755.
Ramsay I. Electromyography in thyrotoxicosis. Q J Med. 1965;34(134):255-267.
Ober KP. Thyrotoxic periodic paralysis in the United States. Medicine (Baltimore). 1992;71(3):109-120.
Kung AW. Clinical review: thyrotoxic periodic paralysis. J Clin Endocrinol Metab. 2006;91(7):2490-2495.
Lin SH, Lin YF. Propranolol rapidly reverses paralysis, hypokalemia, and hypophosphatemia in thyrotoxic periodic paralysis. Am J Kidney Dis. 2001;37(3):620-623.
Ahlawat SK, Sachdev A. Hypokalaemic paralysis. Postgrad Med J. 1999;75(882):193-197.
Patten BM, Bilezikian JP, Mallette LE, Prince A, Engel WK, Aurbach GD. Neuromuscular disease in primary hyperparathyroidism. Ann Intern Med. 1974;80(2):182-193.
Turken SA, Cafferty M, Silverberg SJ, et al. Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. Am J Med. 1989;87(5):553-557.
Abbasi B, Sharif N, DiCristofano J, et al. Proximal myopathy revealing primary hyperparathyroidism. Clin Cases Miner Bone Metab. 2014;11(3):233-236.
Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab. 2007;92(8):3001-3005.
Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nat Rev Endocrinol. 2018;14(2):115-125.
Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. Lancet. 2018;391(10116):168-178.
Marcocci C, Cetani F. Clinical practice. Primary hyperparathyroidism. N Engl J Med. 2011;365(25):2389-2397.
Bandeira F, Griz L, Chaves N, Carvalho NC, Borges LM, Lazaretti-Castro M, et al. Diagnosis and management of primary hyperparathyroidism. Arq Bras Endocrinol Metabol. 2014;58(5):587-595.
Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab. 2014;99(10):3561-3569.
Gallagher EJ, LeRoith D. Obesity and diabetes: the increased risk of cancer and cancer-related mortality. Physiol Rev. 2015;95(3):727-748.
Kyriakides T, Angelini C, Schaefer J, et al. EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia. Eur J Neurol. 2010;17(6):767-773.
Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000;342(17):1266-1271.
Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93(5):1526-1540.
Raff H, Findling JW. A physiologic approach to diagnosis of the Cushing syndrome. Ann Intern Med. 2003;138(12):980-991.
Carroll T, Raff H, Findling JW.

Late-night salivary cortisol for the diagnosis of Cushing syndrome. Arq Bras Endocrinol Metabol. 2009;53(2):190-195. 49. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343-1421. 50. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18(6):988-1028.

Word count: approximately 2,500 words

Author declaration: This review represents a synthesis of current evidence-based approaches to proximal muscle weakness with emphasis on practical clinical application for postgraduate medical education.